TP53 and cancer: With Oct4 and Sox2 reprogramming, p53-knockout cells merely maintained their pluripotent capacity in vivo, whereas mutant p53 (R172H) mouse cells gave rise to malignant tumors, with inherent oncogenic GOF attributable to the involvement of Klf4 [14].